David A. Siegel Athira Pharma, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 253,300 shares of ATHA stock, worth $93,721. This represents 0.0% of its overall portfolio holdings.

Number of Shares

253,300

Previous 337,600 24.97%

Holding current value

$93,721

Previous $151,000 1.32%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.42 - $0.8 $35,406 - $67,440	-84,300 Reduced 24.97%	253,300 $149,000
Q3 2024 Nov 14, 2024	SELL	$0.42 - $3.43 $9,786 - $79,919	-23,300 Reduced 6.46%	337,600 $151,000
Q2 2024 Aug 14, 2024	SELL	$1.92 - $2.71 $16,512 - $23,306	-8,600 Reduced 2.33%	360,900 $956,000
Q1 2024 May 15, 2024	BUY	$2.24 - $4.15 $158,816 - $294,235	70,900 Added 23.74%	369,500 $1.01 Million
Q4 2023 Feb 14, 2024	BUY	$1.39 - $2.46 $27,104 - $47,970	19,500 Added 6.99%	298,600 $725,000
Q3 2023 Nov 14, 2023	SELL	$1.9 - $3.16 $67,260 - $111,864	-35,400 Reduced 11.26%	279,100 $563,000
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $424,092 - $645,123	-179,700 Reduced 36.36%	314,500 $927,000
Q1 2023 May 15, 2023	BUY	$2.26 - $4.22 $366,345 - $684,062	162,100 Added 48.81%	494,200 $1.24 Million
Q4 2022 Feb 14, 2023	SELL	$2.76 - $3.71 $42,228 - $56,763	-15,300 Reduced 4.4%	332,100 $1.05 Million
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $708,474 - $957,528	241,800 Added 228.98%	347,400 $1.03 Million
Q2 2022 Aug 15, 2022	BUY	$2.74 - $13.43 $190,156 - $932,042	69,400 Added 191.71%	105,600 $322,000
Q1 2022 May 16, 2022	SELL	$8.96 - $13.51 $86,016 - $129,696	-9,600 Reduced 20.96%	36,200 $489,000
Q4 2021 Feb 14, 2022	SELL	$9.17 - $16.39 $266,847 - $476,949	-29,100 Reduced 38.85%	45,800 $597,000
Q3 2021 Nov 15, 2021	BUY	$9.15 - $11.09 $360,510 - $436,946	39,400 Added 110.99%	74,900 $703,000
Q2 2021 Aug 16, 2021	SELL	$10.24 - $20.87 $165,888 - $338,094	-16,200 Reduced 31.33%	35,500 $364,000
Q1 2021 May 17, 2021	SELL	$16.9 - $29.77 $96,329 - $169,689	-5,700 Reduced 9.93%	51,700 $951,000
Q4 2020 Feb 16, 2021	BUY	$16.48 - $34.3 $945,952 - $1.97 Million	57,400 New	57,400 $1.97 Million

Others Institutions Holding ATHA

# of Institutions

Shares Held

18.8M

Call Options Held

17.2K

Put Options Held

800

View Full List

About Athira Pharma, Inc.

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $14M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

More about ATHA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account